Shots: During the initial part of conversation, Sergey discussed details about the BDTX-1535 and the trial design of the P-I study where 1535 is being investigated in NSCLC and GBM patients He then discussed the insights drawn from the first 51 patients recruited in the dose escalation part of the P-I study In the final…
